Algert Global LLC Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Algert Global LLC increased its stake in Ultragenyx Pharmaceutical Inc. by 57.4% during the first quarter, owning 130,320 shares valued at $4.7 million.
• Multiple institutional investors, including Barclays PLC and First Trust Advisors LP, significantly enhanced their positions in Ultragenyx, collectively resulting in institutional ownership of 97.67% in the company.
• Ultragenyx reported a quarterly earnings per share of ($1.17), surpassing estimates, with a revenue increase of 13.2% year-over-year, reflecting a positive trend amid ongoing challenges.

Algert Global LLC raised its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 57.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 130,320 shares of the biopharmaceutical company's stock after purchasing an additional 47,527 shares during the period. Algert Global LLC owned 0.14% of Ultragenyx Pharmaceutical worth $4,719,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. California State Teachers Retirement System grew its holdings in Ultragenyx Pharmaceutical by 0.3% during the 4th quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock worth $3,284,000 after acquiring an additional 268 shares in the last quarter. GAMMA Investing LLC lifted its position in Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the last quarter. Xponance Inc. raised its position in shares of Ultragenyx Pharmaceutical by 2.8% during the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock worth $455,000 after buying an additional 347 shares in the last quarter. BOKF NA raised its position in shares of Ultragenyx Pharmaceutical by 5.0% during the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after buying an additional 382 shares in the last quarter. Finally, Oak Ridge Investments LLC grew its stake in shares of Ultragenyx Pharmaceutical by 2.3% in the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock worth $643,000 after purchasing an additional 395 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director owned 15,344 shares in the company, valued at $573,712.16. This represents a 13.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on RARE shares. Cantor Fitzgerald dropped their target price on shares of Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. Wedbush reduced their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. HC Wainwright upgraded shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price for the company in a research note on Monday, July 28th. Wells Fargo & Company dropped their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Finally, William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective on the stock. Eleven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $81.50.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock traded up $0.26 during midday trading on Friday, reaching $29.78. The company had a trading volume of 1,267,904 shares, compared to its average volume of 1,298,327. The stock has a fifty day moving average price of $31.85 and a 200 day moving average price of $35.89. The firm has a market cap of $2.87 billion, a PE ratio of -5.39 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $25.81 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The company's revenue was up 13.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.